In light of the recent disruptions and challenges posed by COVID-19, there has been an increase in activity in promoting the use of technology in clinical trials. This article reviews recent statements from the FDA (U.S. regulator), the MHRA Inspectorate (U.K. regulator), various institutional review boards (IRBs), and ACRO (Association of Clinical Research Organizations) regarding the current situation.
To better understand current views on technology software solutions that support clinical research and development (collectively referred to as eClinical software solutions), especially on a unified platform, we surveyed current and former technology decision-makers representing large to midsize pharmaceutical companies and CROs.